Patents and patent applications
DexTech’s inventions are protected by patents, that give the company exclusive rights. In other words, DexTech owns all patents and patent applications granted since the company was founded in 2004. Patent applications have been made in countries where advanced medical research and development are prevalent, and in those countries that represent major markets for medications. Patents are usually applicable for 20 years, but for medications they can be extended by up to five years in some cases. DexTech seeks to maintain strong protection of future medications through proactive management of its patent portfolio. This policy is further reinforced by protection of the company’s assets and rights through unambiguous agreements, strong patents and judicious handling of the know-how published.
DexTech’s patent portfolio consists of four patent families containing approved patents and patent applications that provide excellent protection for the company’s candidate medications and technology platform. The portfolio has a relevant geographical spread for DexTech. The company’s three patent families and applications are closely related, and each family is therefore relevant to all the company’s candidate medications, and the GuaDex platform.
DexTech’s patent portfolio is a vital asset for the company, and a comprehensive patent portfolio prevents competitors from encroaching into the company’s patented field. Patents give market exclusivity during their lifetime. No patents or patents that fail to provide adequate protection for the company from competitors can reduce the chances of license agreements, which would affect not only profitability but also the company’s value. The company’s patent portfolio is managed by the BOCO patent bureau in Helsinki, Finland.
Patent family 1 – formed in 1999
Patent family 1 describes how the positively-charged substance CatDex selectively concentrates in the tumour tissue, i.e. selectively relatively normal tissue.
It includes approved patents in Australia, Canada, the USA, and Europe (registered in Belgium, Switzerland, Germany, France, Great Britain, Italy and Sweden). The patent is valid until 12 October 2019.
Patent family 2 – formed in 2008
Patent family 2, the GuaDex patent, is a further development of patent family 1, and describes its anti-tumour cell properties against a range of tumours and tumour cell cultures.
It includes approved patents in China, Israel, Mexico, Kanada, Japan, the USA, and Europe (registered in Belgium, Switzerland, Finland, Germany, France, Great Britain, Italy and Sweden). The patent is valid until 06 March 2028. Patent applications are pending for Brazil.
Patent family 3 – formed in 2008
Patent family 3, the OsteoDex patent, is a GuaDex molecule with an additional component – a bisphosphonate, that has selectivity for the skeleton, i.e. in areas with bone metastases.
It includes approved patents in China, Japan, Canada, Israel, Mexico and Europe (registered in Switzerland, Germany, France, Great Britain, Italy and Sweden). The patent is valid until 7 April 2028. Patent applications are pending for Brazil.
Patent family 4 – formed in 2016
Patent family 4, PSMA-Dx is a development from the GuaDex platform for targeting prostate specific membrane antigen (PSMA) that is overexpressed in CRPC. PSMA-Dx is model compound for either therapy with radionuclides or cytostatics, patents pending.
Click on attachment for patent status: